Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$5.75
-0.2%		$7.08
$5.13
▼
$20.40
$18.12M1.3425,695 shs11,771 shs
Daxor Corporation stock logo
DXR
Daxor
$11.45
-1.5%		$10.52
$8.56
▼
$14.76
$66.85M0.2639,649 shs26,884 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$6.08
+5.2%		$4.66
$9.41
▼
$13.80
$68.17M0.09205,918 shs1.14 million shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$7.61
-0.3%		$6.43
$2.21
▼
$9.33
$95.57M1.47136,250 shs174,534 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.00%-10.30%-7.59%-34.41%-68.20%
Daxor Corporation stock logo
DXR
Daxor
0.00%-0.17%+15.35%+17.14%+0.26%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
+5.19%-0.65%+9.55%+52.38%+140.32%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00%+32.58%+21.37%+6.43%+197.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$5.75
-0.2%		$7.08
$5.13
▼
$20.40
$18.12M1.3425,695 shs11,771 shs
Daxor Corporation stock logo
DXR
Daxor
$11.45
-1.5%		$10.52
$8.56
▼
$14.76
$66.85M0.2639,649 shs26,884 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$6.08
+5.2%		$4.66
$9.41
▼
$13.80
$68.17M0.09205,918 shs1.14 million shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$7.61
-0.3%		$6.43
$2.21
▼
$9.33
$95.57M1.47136,250 shs174,534 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.00%-10.30%-7.59%-34.41%-68.20%
Daxor Corporation stock logo
DXR
Daxor
0.00%-0.17%+15.35%+17.14%+0.26%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
+5.19%-0.65%+9.55%+52.38%+140.32%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00%+32.58%+21.37%+6.43%+197.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
2.00
Hold$107.501,769.57% Upside
Daxor Corporation stock logo
DXR
Daxor
2.50
Moderate BuyN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
0.00
N/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
3.00
Buy$13.0070.83% Upside

Current Analyst Ratings Breakdown

Latest CTSO, NRXS, HSAQ, and DXR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/6/2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Daxor Corporation stock logo
DXR
Daxor
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$37.06M0.49N/AN/A$1.88 per share3.06
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/A($0.62) per shareN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$5.32M17.98N/AN/A($0.27) per share-28.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$8.20M-$5.80N/AN/AN/A-48.94%-431.65%-41.94%11/12/2026 (Estimated)
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
-$380KN/AN/AN/AN/AN/AN/A-2.38%N/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
-$14.63M-$0.78N/AN/AN/A-492.76%N/A-641.25%11/17/2026 (Estimated)

Latest CTSO, NRXS, HSAQ, and DXR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.80-$0.07+$0.73-$1.40$9.39 million$9.63 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
4.70
0.66
0.50
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/A
0.17
0.61
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/A
0.24
0.23

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
Daxor Corporation stock logo
DXR
Daxor
1.34%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
89.71%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
11.77%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.80%
Daxor Corporation stock logo
DXR
Daxor
51.50%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
21.90%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
21.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
1293.15 million2.91 millionOptionable
Daxor Corporation stock logo
DXR
Daxor
375.84 million2.83 millionNot Optionable
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
411.21 million8.76 millionNot Optionable
NeurAxis, Inc. stock logo
NRXS
NeurAxis
2412.56 million6.09 millionNot Optionable

Recent News About These Companies

NeurAxis Shares Surge 25% On New Insurer Coverage
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691580/neuraxis-shares-surge-25-on-new-insurer-coverage.aspx
NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691572/neuraxis-expands-penfs-coverage-by-18-million-lives-as-ib-stim-adoption-grows-stock-up.aspx
Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691622/biotech-stocks-see-fresh-catalysts-tempest-datameds-neuraxis-maia.aspx
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363241/0/en/neuraxis-announces-medical-coverage-policy-milestone-expanding-access-to-over-18-million-additional-covered-lives.html
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363046/0/en/neuraxis-to-participate-in-the-lytham-partners-fall-2026-investor-conference.html
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?
September 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2990000/neuraxis-gains-nearly-137-in-a-year-what-s-driving-the-stock?cid=cs-stocknewsapi-ft-microcap_article|investment_ideas-2990000
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946498-neuraxis-inc-nrxs-presents-at-iaccess-alpha-virtual-best-ideas-fall-investment-conference
Is Kodak having a "Kodak moment?" 2 watchlist stocks.
September 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2988740/is-kodak-having-a-kodak-moment-2-watchlist-stocks?cid=cs-stocknewsapi-ft-microcap_article-2988740
NeurAxis Enhances Executive and Director Equity Compensation
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuraxis-enhances-executive-and-director-equity-compensation?utm_source=marketbeat.com&utm_medium=referral
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975155/nrxs-stock-dips-post-q2-earnings-despite-revenue-surge-gross-margin-up?cid=cs-stocknewsapi-ft-microcap_article|earnings-2975155
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neuraxis-nrxs-q2-2026-earnings-012824060.html
Neuraxis Inc (NRXS) (Q2 2026) Earnings Call Highlights: Revenue Surges 116% as Payer Coverage ...
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neuraxis-inc-nrxs-q2-2026-210033296.html
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934924-neuraxis-inc-nrxs-q2-2026-earnings-call-transcript
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/neuraxis-reports-record-second-quarter-2026-financial-results-driven-by-116-year-over-year-revenue-growth-1036440491
NeurAxis Announces Additional Mid-Atlantic Coverage for IB-Stim PENFS Therapy, Expanding Access to Over 500,000 Lives
August 4, 2026  |  quiverquant.comQ
NeurAxis Expands Payer Coverage with New Policies
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338132/0/en/neuraxis-expands-payer-coverage-with-new-policies.html
NeurAxis, Inc. to Report Second Quarter 2026 Financial Results on August 11 and Host Conference Call
July 28, 2026  |  quiverquant.comQ
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334108/0/en/neuraxis-to-host-second-quarter-2026-results-and-business-update-call-on-tuesday-august-11-2026.html
NeurAxis Declares Q2 Stock Dividend on Series B
July 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuraxis-declares-q2-stock-dividend-on-series-b?utm_source=marketbeat.com&utm_medium=referral
Neuraxis (NRXS) Stock Forecast & Price Target
June 17, 2026  |  investing.comhttps://www.investing.com/equities/neuraxis-consensus-estimates

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$5.75 -0.01 (-0.17%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$5.74 -0.01 (-0.10%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Daxor stock logo

Daxor NASDAQ:DXR

$11.45 -0.18 (-1.55%)
Closing price 09/18/2026 03:48 PM Eastern
Extended Trading
$11.76 +0.31 (+2.74%)
As of 09/18/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Health Sciences Acquisitions Co. 2 stock logo

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$6.08 +0.30 (+5.19%)
As of 09/18/2026

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

NeurAxis stock logo

NeurAxis NASDAQ:NRXS

$7.61 -0.02 (-0.26%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$7.57 -0.04 (-0.49%)
As of 09/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas